시장보고서

상품코드

2008776

유아 경련 치료제 시장 : 약제 클래스별, 약제 유형, 투여량, 투여 경로, 유통 채널, 최종사용자 및 지역별(2026-2034년)

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others ), Dosage, Route of Administration, Distribution Channel, End User, and Region 2026-2034

발행일: 2026년 04월 | 리서치사: 구분자

IMARC | 페이지 정보: 영문 148 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트 등의 Copy&Paste도 불가능합니다.

US $ 3,999

￦ 6,000,000

PDF & Excel (5 User License)

PDF & Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 불가능합니다. 인쇄는 5부까지 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,999

￦ 7,500,000

PDF & Excel (Corporate License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 가능합니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,999

￦ 9,000,000

※ 부가세 별도

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 유아 경련 치료제 시장 규모는 2025년에 39억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 53억 달러에 달하며, 2026-2034년에 CAGR 3.38%로 성장할 것으로 예측하고 있습니다. 영아 발작의 유병률 증가, 대중의 건강 인식 향상으로 인한 조기 진단 증가, 제품 승인 건수 증가 및 강력한 파이프라인 의약품의 존재 등이 시장을 주도하는 주요 요인으로 작용하고 있습니다.

영아 경련 치료는 보통 생후 4개월에서 1세까지의 영유아의 발작 및 간질 증후군 치료에 사용되는 치료법을 말합니다. 경련 발작은 몸이 갑자기 경직되고, 팔, 다리, 머리가 앞으로 구부러지고, 등이 뒤틀리고, 짧고 미세한 발작이 일어나는 것이 특징입니다. 영아 경련은 뇌종양, 출생시 외상, 뇌 감염, 유전적 돌연변이 등으로 인해 발생할 수 있습니다. 영아 경련은 스테로이드, 코르티코트로핀 주사제, 글루코코르티코이드를 이용한 호르몬 요법, 항경련제 등 다양한 치료법이 있습니다. 영아 경련의 치료는 경련 발작 발생 후 3주 이내에 시작하면 지속적인 효과를 얻을 가능성이 높으며, 단독요법 또는 병용요법으로 치료합니다. 영아경련의 진단은 신체검사, 신경학적 검사, 뇌 MRI 검사, 혈액 및 소변 검사 등을 통해 이루어집니다.

영아 경련 치료제 시장 동향:

신생아의 영아 경련 유병률 증가는 시장 성장을 이끄는 중요한 요인입니다. 이는 전 세계 출산율의 현저한 상승에 기인한다고 볼 수 있습니다. 이에 따라 제품 승인 건수의 증가와 강력한 파이프라인 약물의 존재가 시장에 긍정적인 영향을 미치고 있습니다. 발작을 감지하여 보호자에게 경고하는 발작 경보 장치의 도입 등 영아 경련 치료의 지속적인 기술 발전이 시장에 활력을 불어넣고 있습니다. 또한 조기 진단 및 치료에 대한 인식이 확산되면서 영아 경련 치료제의 보급률이 높아져 시장 성장을 촉진하고 있습니다. 그러나 낮은 치료 성공률, 높은 치료비, 엄격한 의약품 승인 규제, 미진단 환자 수 증가 등 다양한 요인으로 인해 영아 경련 치료제 시장의 성장을 저해하고 있습니다. 한편, 이 질환에 대한 인식을 높이기 위해 여러 국가의 정부 및 민간 기관에서 시행하고 있는 유익한 노력과 프로그램들이 시장에 긍정적인 전망을 가져다주고 있습니다. 또한 주요 시장 기업이 더 높은 성공률을 가진 혁신적인 약물 개발에 초점을 맞춘 광범위한 연구개발(R&D) 활동이 시장을 주도하고 있습니다. 이 외에도 헬스케어 관련 지출 증가, 제휴 및 파트너십, 인수합병(M&A) 증가, 급속한 도시화, 가처분 소득 수준 상승 등이 시장 성장에 기여하는 요인으로 꼽힙니다.

The global infantile spasms therapeutics market size reached USD 3.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.38% during 2026-2034. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.

Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures . Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.

INFANTILE SPASMS THERAPEUTICS MARKET TRENDS:

The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.

KEY MARKET SEGMENTATION:

Therapeutic Class Insights:

Anticonvulsants
Corticosteroids
Others

Drug Type Insights:

Vigabatrin
Adrenocorticotropic Hormone
Others (Phase III)

Dosage Insights:

Solid
Liquid

Route of Administration Insights:

Oral
Parenteral
Others

Distribution Channel Insights:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

End User Insights:

Hospitals
Clinics
Others

Regional Insights:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the global infantile spasms therapeutics market?

2. What is the expected growth rate of the global infantile spasms therapeutics market during 2026-2034?

3. What are the key factors driving the global infantile spasms therapeutics market?

4. What has been the impact of COVID-19 on the global infantile spasms therapeutics market?

5. What is the breakup of the global infantile spasms therapeutics market based on the therapeutic class?

6. What is the breakup of the global infantile spasms therapeutics market based on the drug type?

7. What is the breakup of the global infantile spasms therapeutics market based on the dosage?

8. What is the breakup of the global infantile spasms therapeutics market based on route of administration?

9. What is the breakup of the global infantile spasms therapeutics market based on the distribution channel?

10. What is the breakup of the global infantile spasms therapeutics market based on the end user?

11. What are the key regions in the global infantile spasms therapeutics market?

12. Who are the key players/companies in the global infantile spasms therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Infantile Spasms Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapeutic Class

6.1 Anticonvulsants
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Corticosteroids
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Drug Type

7.1 Vigabatrin
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Adrenocorticotropic Hormone
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Others (Phase III)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Dosage

8.1 Solid
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Liquid
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

9.1 Oral
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Parenteral
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

10.1 Hospital Pharmacy
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Retail Pharmacy
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Online Pharmacy
- 10.3.1 Market Trends
- 10.3.2 Market Forecast

11 Market Breakup by End User

11.1 Hospitals
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
11.2 Clinics
- 11.2.1 Market Trends
- 11.2.2 Market Forecast
11.3 Others
- 11.3.1 Market Trends
- 11.3.2 Market Forecast

12 Market Breakup by Region

12.1 North America
- 12.1.1 United States
  - 12.1.1.1 Market Trends
  - 12.1.1.2 Market Forecast
- 12.1.2 Canada
  - 12.1.2.1 Market Trends
  - 12.1.2.2 Market Forecast
12.2 Asia-Pacific
- 12.2.1 China
  - 12.2.1.1 Market Trends
  - 12.2.1.2 Market Forecast
- 12.2.2 Japan
  - 12.2.2.1 Market Trends
  - 12.2.2.2 Market Forecast
- 12.2.3 India
  - 12.2.3.1 Market Trends
  - 12.2.3.2 Market Forecast
- 12.2.4 South Korea
  - 12.2.4.1 Market Trends
  - 12.2.4.2 Market Forecast
- 12.2.5 Australia
  - 12.2.5.1 Market Trends
  - 12.2.5.2 Market Forecast
- 12.2.6 Indonesia
  - 12.2.6.1 Market Trends
  - 12.2.6.2 Market Forecast
- 12.2.7 Others
  - 12.2.7.1 Market Trends
  - 12.2.7.2 Market Forecast
12.3 Europe
- 12.3.1 Germany
  - 12.3.1.1 Market Trends
  - 12.3.1.2 Market Forecast
- 12.3.2 France
  - 12.3.2.1 Market Trends
  - 12.3.2.2 Market Forecast
- 12.3.3 United Kingdom
  - 12.3.3.1 Market Trends
  - 12.3.3.2 Market Forecast
- 12.3.4 Italy
  - 12.3.4.1 Market Trends
  - 12.3.4.2 Market Forecast
- 12.3.5 Spain
  - 12.3.5.1 Market Trends
  - 12.3.5.2 Market Forecast
- 12.3.6 Russia
  - 12.3.6.1 Market Trends
  - 12.3.6.2 Market Forecast
- 12.3.7 Others
  - 12.3.7.1 Market Trends
  - 12.3.7.2 Market Forecast
12.4 Latin America
- 12.4.1 Brazil
  - 12.4.1.1 Market Trends
  - 12.4.1.2 Market Forecast
- 12.4.2 Mexico
  - 12.4.2.1 Market Trends
  - 12.4.2.2 Market Forecast
- 12.4.3 Others
  - 12.4.3.1 Market Trends
  - 12.4.3.2 Market Forecast
12.5 Middle East and Africa
- 12.5.1 Market Trends
- 12.5.2 Market Breakup by Country
- 12.5.3 Market Forecast

13 Drivers, Restraints, and Opportunities

13.1 Overview
13.2 Drivers
13.3 Restraints
13.4 Opportunities

14 Value Chain Analysis

15 Porters Five Forces Analysis

15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
- 17.3.1 H. Lundbeck A/S
  - 17.3.1.1 Company Overview
  - 17.3.1.2 Product Portfolio
  - 17.3.1.3 Financials
  - 17.3.1.4 SWOT Analysis
- 17.3.2 Mallinckrodt plc
  - 17.3.2.1 Company Overview
  - 17.3.2.2 Product Portfolio
  - 17.3.2.3 Financials
- 17.3.3 ORPHELIA Pharma
  - 17.3.3.1 Company Overview
  - 17.3.3.2 Product Portfolio
- 17.3.4 Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
  - 17.3.4.1 Company Overview
  - 17.3.4.2 Product Portfolio